Arvinas to Present at Upcoming Investor Conferences
Arvinas to Present at Upcoming Investor Conferences
NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
康涅狄格州紐黑文，2024年5月2日（GLOBE NEWSWIRE）——開發一種基於靶向蛋白質降解的新藥物的臨床階段生物技術公司Arvinas, Inc.（納斯達克股票代碼：ARVN）今天宣佈，管理層將參加即將舉行的兩次投資者會議：
-
BofA Securities 2024 Healthcare Conference on Tuesday, May 14 at 3:00 p.m. PT in Las Vegas.
- Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company's website.
- 美銀證券2024年醫療保健會議將於太平洋時間5月14日星期二下午3點在拉斯維加斯舉行。
- 首席醫學官諾亞·伯科維茨醫學博士、博士和首席商務官蘭迪·蒂爾博士將參加爐邊談話。將提供該演示文稿的網絡現場直播 這裏 以及公司網站的 “活動和演示” 部分。
-
UBS Spring Biotech Conferences on Tuesday, May 21.
- Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in investor 1x1 meetings.
- 瑞銀春季生物技術會議將於5月21日星期二舉行。
- 首席醫學官諾亞·伯科維茨醫學博士、博士和首席商務官蘭迪·蒂爾博士將參加投資者1x1會議。
About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and "undruggable" targets, the company has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-102 for the treatment of patients with neurodegenerative disorders. For more information, visit www.arvinas.com.
關於阿維納斯
Arvinas是一家處於臨床階段的生物技術公司，致力於通過發現、開發和商業化降解致病蛋白的療法，改善患有使人衰弱和危及生命的疾病的患者的生活。Arvinas 使用其專有的 PROTAC Discovery Engine 平台用於設計針對嵌合體或 PROTAC 的蛋白水解 靶向蛋白質降解劑，旨在利用人體自身的天然蛋白質處置系統，有選擇地高效地降解和去除致病蛋白。除了針對經過驗證和 “不可藥用” 的靶標的強大臨床前PROTAC蛋白降解劑產品線外，該公司還有四個臨床階段研究項目：用於治療局部晚期或轉移性ER+/HER2-乳腺癌患者的vepdegestrant（ARV-471）；用於治療轉移性去勢抵抗性前列腺癌男性的 ARV-766 和巴德加魯胺；以及用於治療轉移性去勢抗性前列腺癌的 ARV-102 神經退行性疾病患者。欲了解更多信息，請訪問 www.arvinas.com。
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
聯繫人
投資者：
傑夫·博伊爾
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kathleen Murphy
+1 (760) 622-3771
Kathleen.Murphy@arvinas.com
媒體：
凱瑟琳·墨菲
+1 (760) 622-3771
Kathleen.Murphy@arvinas.com